Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 8/20 | 0.66 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 9/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | CALML3 | P27482 | 1/20 | 0.45 |
| ▸ | SDHA | P31040 | 1/20 | 0.45 |
| ▸ | F10 | P00742 | 6/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5833513 | 1.00 | MAOA (0.66) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL5833372 | 0.88 | MAOA (0.57) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL5833613 | 0.84 | MAOA (0.61) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL5833617 | 0.84 | MAOA (0.61) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL7081049 | 0.84 | MAOA (0.46) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL7081053 | 0.84 | MAOA (0.46) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL4013233 | 0.84 | MAOA (0.46) | MAOAMAOBLMNAPTGS1CALML3 | |
| SCHEMBL6765242 | 0.83 | MAOA (0.63) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL5834671 | 0.83 | MAOA (0.63) | MAOACYP2E1MAOBLMNAPTGS1 | |
| SCHEMBL2890293 | 0.83 | MAOA (0.49) | MAOACYP2E1MAOBLMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087629-B2 | Useful activity against Gram-positive pathogens and, in particular, against various strains exhibiting resistance to vancomycin and against E. faecium strains resistant to both aminoglycosides and clinically used beta-lactams | ASTRAZENECA AB (SE) | 2006-08-08 | — | — | US | disclosed |
| US-6734200-B1 | ANTIBIOTIC COMPOUNDS CONTAINING A SUBSTITUTED OXAZOLIDINONE RING; ACTIVITY AGAINST GRAM-POSITIVE PATHOGENS | ASTRAZENECA AB (SE) | 2004-05-11 | — | — | US | disclosed |